• Je něco špatně v tomto záznamu ?

∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers

Y. Liu, M. Nekulova, R. Nenutil, I. Horakova, MV. Appleyard, K. Murray, J. Holcakova, M. Galoczova, P. Quinlan, LB. Jordan, CA. Purdie, B. Vojtesek, AM. Thompson, PJ. Coates

. 2020 ; 6 (1) : 83-93. [pub] 20191206

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020828

ΔNp63, also known as p40, regulates stemness of normal mammary gland epithelium and provides stem cell characteristics in basal and HER2-driven murine breast cancer models. Whilst ΔNp63/p40 is a characteristic feature of normal basal cells and basal-type triple-negative breast cancer, some receptor-positive breast cancers express ΔNp63/p40 and its overexpression imparts cancer stem cell-like properties in ER+ cell lines. However, the incidence of ER+ and HER2+ tumours that express ΔNp63/p40 is unclear and the phenotype of ΔNp63/p40+ cells in these tumours remains uncertain. Using immunohistochemistry with p63 isoform-specific antibodies, we identified a ΔNp63/p40+ tumour cell subpopulation in 100 of 173 (58%) non-triple negative breast cancers and the presence of this population associated with improved survival in patients with ER- /HER2+ tumours (p = 0.006). Furthermore, 41% of ER+ /PR+ and/or HER2+ locally metastatic breast cancers expressed ΔNp63/p40, and these cells commonly accounted for <1% of the metastatic tumour cell population that localised to the tumour/stroma interface, exhibited an undifferentiated phenotype and were CD44+ /ALDH- . In vitro studies revealed that MCF7 and T47D (ER+ ) and BT-474 (HER2+ ) breast cancer cell lines similarly contained a small subpopulation of ΔNp63/p40+ cells that increased in mammospheres. In vivo, MCF7 xenografts contained ΔNp63/p40+ cells with a similar phenotype to primary ER+ cancers. Consistent with tumour samples, these cells also showed a distinct location at the tumour/stroma interface, suggesting a role for paracrine factors in the induction or maintenance of ΔNp63/p40. Thus, ΔNp63/p40 is commonly present in a small population of tumour cells with a distinct phenotype and location in ER+ and/or HER2+ human breast cancers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020828
003      
CZ-PrNML
005      
20210830102451.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cjp2.149 $2 doi
035    __
$a (PubMed)31591823
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Liu, Yajing $u NCRC, University of Michigan, Ann Arbor, MI, USA
245    10
$a ∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers / $c Y. Liu, M. Nekulova, R. Nenutil, I. Horakova, MV. Appleyard, K. Murray, J. Holcakova, M. Galoczova, P. Quinlan, LB. Jordan, CA. Purdie, B. Vojtesek, AM. Thompson, PJ. Coates
520    9_
$a ΔNp63, also known as p40, regulates stemness of normal mammary gland epithelium and provides stem cell characteristics in basal and HER2-driven murine breast cancer models. Whilst ΔNp63/p40 is a characteristic feature of normal basal cells and basal-type triple-negative breast cancer, some receptor-positive breast cancers express ΔNp63/p40 and its overexpression imparts cancer stem cell-like properties in ER+ cell lines. However, the incidence of ER+ and HER2+ tumours that express ΔNp63/p40 is unclear and the phenotype of ΔNp63/p40+ cells in these tumours remains uncertain. Using immunohistochemistry with p63 isoform-specific antibodies, we identified a ΔNp63/p40+ tumour cell subpopulation in 100 of 173 (58%) non-triple negative breast cancers and the presence of this population associated with improved survival in patients with ER- /HER2+ tumours (p = 0.006). Furthermore, 41% of ER+ /PR+ and/or HER2+ locally metastatic breast cancers expressed ΔNp63/p40, and these cells commonly accounted for <1% of the metastatic tumour cell population that localised to the tumour/stroma interface, exhibited an undifferentiated phenotype and were CD44+ /ALDH- . In vitro studies revealed that MCF7 and T47D (ER+ ) and BT-474 (HER2+ ) breast cancer cell lines similarly contained a small subpopulation of ΔNp63/p40+ cells that increased in mammospheres. In vivo, MCF7 xenografts contained ΔNp63/p40+ cells with a similar phenotype to primary ER+ cancers. Consistent with tumour samples, these cells also showed a distinct location at the tumour/stroma interface, suggesting a role for paracrine factors in the induction or maintenance of ΔNp63/p40. Thus, ΔNp63/p40 is commonly present in a small population of tumour cells with a distinct phenotype and location in ER+ and/or HER2+ human breast cancers.
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové biomarkery $x analýza $x metabolismus $7 D014408
650    _2
$a nádory prsu $x genetika $x metabolismus $x patologie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a heterografty $7 D064593
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a nádorové kmenové buňky $x metabolismus $x patologie $7 D014411
650    _2
$a fenotyp $7 D010641
650    _2
$a receptor erbB-2 $x genetika $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x genetika $x metabolismus $7 D011960
650    _2
$a transkripční faktory $x metabolismus $7 D014157
650    _2
$a nádorové supresorové proteiny $x metabolismus $7 D025521
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nekulova, Marta $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Nenutil, Rudolf $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Horakova, Iva $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Appleyard, M Virginia $u Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
700    1_
$a Murray, Karen $u Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
700    1_
$a Holcakova, Jitka $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Galoczova, Michaela $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Quinlan, Philip $u Advanced Data Analysis Centre, University of Nottingham, Nottingham, UK
700    1_
$a Jordan, Lee B $u Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK
700    1_
$a Purdie, Colin A $u Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK
700    1_
$a Vojtesek, Borivoj $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Thompson, Alastair M $u Division of Surgical Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA
700    1_
$a Coates, Philip J $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
773    0_
$w MED00205747 $t The journal of pathology. Clinical research $x 2056-4538 $g Roč. 6, č. 1 (2020), s. 83-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31591823 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102452 $b ABA008
999    __
$a ok $b bmc $g 1691419 $s 1141274
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 6 $c 1 $d 83-93 $e 20191206 $i 2056-4538 $m The journal of pathology. Clinical research $n J Pathol Clin Res $x MED00205747
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace